Loading data for HOWL — first visit, this takes a few seconds.

Alerta

Werewolf Therapeutics Inc... (HOWL)

NasdaqCM: HOWL · Precio en tiempo real · USD

0.41

+0.00 (0.00%)

Al cierre: Aug 18, 2026, 8:00 PM

0.00% (1D)

No hay datos disponibles

Precio de compra	0.29
Capitalización de mercado	19.89M
Ingresos (TTM)	21M
Beneficio neto (TTM)	-34.61M
Beta	0.29
EPS (TTM)	-0.75
Ratio PER (TTM)	n/a
Adelante PE	-0.41
P/B (TTM)	1.22
P/S (TTM)	0.95
Earnings Date	Oct 30, 2026

Precio de venta	0.53
Volumen	58,525
Volumen medio (20D)	706,629
Abierto	0.41
Anterior Cerrar	0.41
Rango del día	0.40 - 0.42
Rango de 52 semanas	0.27 - 2.38
analista	n/a
Precio objetivo	n/a
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de HOWL

Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead prod...

[Leer más]

Industria Biotechnology

Sector Healthcare

IPO Fecha Apr 30, 2021

Empleados 39

Bolsa de Valores NasdaqCM

Símbolo bursátil HOWL

Sitio web https://werewolftx.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Werewolf Therapeutics fueron 0, una disminución de -100% en comparación con 1.89M del año anterior. Las ganancias fueron -60.82M, una disminución de -13.75%.

Estados financieros

Sorpresa de resultados

Werewolf Therapeutics ha publicado sus resultados trimestrales en Jul 31, 2026:

Ingresos de $21M falla las estimaciones por $0, con Infinity% Crecimiento interanual.

EPS de 0.14 supera las estimaciones en 0.46, con 135.00% Crecimiento interanual.

Próxima publicación de resultados

Está previsto que Werewolf Therapeutics Inc. publique sus resultados el Oct 30, 2026, antes de que se abra el mercado.
Los analistas proyectan ingresos de ... Actualizar

Noticias

2 semanas hace · Zacks

JAZZ Q2 Earnings Miss, Sales Beat, Stock Jumps on Raised '26 View

Jazz Pharmaceuticals tops Q2 sales estimates and raises its 2026 revenue outlook despite an EPS miss, as strong oncology and neuroscience demand lifts shares.

3 meses hace · Simply Wall St.

Here's Why We're A Bit Worried About Werewolf Therapeutics' (NASDAQ:HOWL) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

7 meses hace · Insider Monkey

Werewolf Therapeutics (HOWL) Eyes 2026 Catalysts Following FDA Guidance and Encouraging INDUKINE Results

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) is included on our list of stocks under $1 that will explode. On December 18, 2025, Werewolf Therapeutics, Inc. (NASDAQ:HOWL) shared a comprehensive pipeline ...

8 meses hace · Zacks

Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know

Werewolf Therapeutics (HOWL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

9 meses hace · Zacks

Insmed Misses on Q3 Earnings, Stock Rises on Strong Brinsupri Uptake

INSM shares jump 16% as Brinsupri's strong debut offset wider Q3 losses, lifting revenue 52% year over year.

Página 1 de 2

Werewolf Therapeutics Inc... (HOWL)